INVICTUS - Trial PACTR202007518001972
Access comprehensive clinical trial information for PACTR202007518001972 through Pure Global AI's free database. This Phase 3 trial is sponsored by Population Health Research Institute and is currently Completed. The study focuses on Cardiology.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
drug
Sponsor & Location
Population Health Research Institute
Bayer AG
Timeline & Enrollment
Phase 3
Jul 29, 2016
Jan 01, 1900
Summary
This program is a comprehensive evaluation of RVHD, AF/flutter and stroke. It includes three major components 1. A multi-centre registry of RVHD2. A prospective, randomized, parallel group, open-label clinical trial of rivaroxaban versus standard VKA therapy to evaluate non-inferiority of rivaroxaban to VKA, with testing for superiority if non-inferiority is satisfied.3. A prospective, randomized, open-label superiority trial comparing rivaroxaban to aspirin in high risk patients either with AF and unsuitable for VKA or without AF and with high risk factors
ICD-10 Classifications
Data Source
Pan Africa Clinical Trials Registry
PACTR202007518001972
Non-Device Trial